Annovis Bio Announces Filing Of Patent
Portfolio Pulse from Bill Haddad
Annovis Bio, a clinical stage drug platform company, has announced the creation of a novel crystalline form of buntanetap (ANVS402) and filed a new composition of matter provisional patent with the U.S. Patent and Trademark Office.
June 27, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Annovis Bio's filing of a new provisional patent for a novel crystalline form of buntanetap (ANVS402) may positively impact its stock price.
The filing of a new provisional patent for a novel crystalline form of buntanetap (ANVS402) by Annovis Bio demonstrates the company's progress in developing innovative therapies for neurodegenerative diseases. This news may be seen as a positive development by investors, potentially leading to an increase in the stock price of ANVS.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100